Looking for New Markers in Pancreatic Cancer

This trial looks for “soluble biomarkers” (markers that can be found in body fluids like blood) for people who have a pancreatic mass and may have pancreatic ductal adenocarcinoma. The goal is to improve how pancreatic cancer is identified, especially using information taken from an endoscopic ultrasound biopsy.

This study looks at “biomarkers” (test signals in tissue or blood) in people with pancreatic cancer. It may help researchers understand the disease better and find ways to predict or track it.

This study looks for markers in tumor tissue that could help find pancreatic cancer earlier. You may be able to join if you are having surgery for a suspected pancreatic tumor and the final diagnosis is a precancerous condition or pancreatic cancer.

This study looks at tumor “markers” (tests on cancer tissue or related information) to understand how you may respond to first-line treatment for pancreatic cancer. Your results may help doctors better predict which treatments work best for different people.

This study looks at “tumor regulatory molecules,” which are substances that may be released by cancer, to improve early pancreatic cancer detection. You may join if you have early, localized pancreatic cancer that can be treated with surgery, or certain pancreatic cysts/fluid collections where doctors are investigating further.

This study tests a new blood test that uses epigenetics (chemical markers on DNA) to help diagnose pancreatic cancer. Researchers want to see if this test can accurately identify pancreatic cancer in people who have had it or are at high risk for developing it.